Positive gamma exposure is building around key upside strikes like $130 and $150, suggesting market makers may be forced to ...

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

Bottom line: Monday's calendar lines up two asymmetric biotech shots: If Sana's six-month data look anything like the first ...